Bluejay Therapeutics, a drug developer focused on serious viral and liver diseases, is considering a US initial public offering, according to people familiar with the matter.
On March 3, 2025, the Securities and Exchange Commission’s Division of Corporation Finance announced that it has enhanced its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback